These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9579835)

  • 1. Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
    de Takats PG; Williams MV; Hawkins R
    Br J Cancer; 1998 Apr; 77(8):1287-93. PubMed ID: 9579835
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
    Hauschild A; Dummer R; Garbe C; Kaufmann R; Schadendorf D; Soyer HP; Stadler R; Tilgen W
    Hautarzt; 1998 Mar; 49(3):167-9. PubMed ID: 9565782
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon alpha-2a and dacarbazine in melanoma.
    Kirkwood JM; Ernstoff MS; Giuliano A; Gams R; Robinson WA; Costanzi J; Pouillart P; Speyer J; Grimm M; Spiegel R
    J Natl Cancer Inst; 1990 Jun; 82(12):1062-3. PubMed ID: 2189999
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current position of the Professional Group of Dermatologic Oncology on high dosage therapy with interferon-alpha-2b].
    Brockmeyer NH; Hoffmann K; Altmeyer P
    Hautarzt; 2000 May; 51(5):360-2. PubMed ID: 10875078
    [No Abstract]   [Full Text] [Related]  

  • 5. Point: Interferon-alpha for adjuvant therapy for melanoma patients.
    Sabel MS; Sondak VK
    J Natl Compr Canc Netw; 2004 Jan; 2(1):61-8. PubMed ID: 19777695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy of melanoma: at what cost?
    Spitler LE
    J Clin Oncol; 2001 Feb; 19(4):1226-8. PubMed ID: 11181688
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recombinant α-2 interferon in preventing the progression of melanoma].
    Korovin SI; Kukushkina MN; Palivets AIu; Fil'chakov FV; Shumilina ES; Ostafĭchuk VV
    Lik Sprava; 2013 Dec; (8):21-30. PubMed ID: 25726673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy of melanoma.
    Shah GD; Chapman PB
    Cancer J; 2007; 13(3):217-22. PubMed ID: 17620773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma.
    Smith KA; Green JA; Eccles JM
    Eur J Cancer; 1992; 28(2-3):438-41. PubMed ID: 1591059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant IFN alpha2 therapy of melanoma.
    Kirkwood JM
    Lancet; 1998 Jun; 351(9120):1901-3. PubMed ID: 9654253
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant interferon alfa-2b for high-risk melanoma.
    Retsas S
    J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
    [No Abstract]   [Full Text] [Related]  

  • 12. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adjuvant therapy of malignant melanoma].
    Hauschild A; Volkenandt M
    Ther Umsch; 1999 Jun; 56(6):324-9. PubMed ID: 10420815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
    Lens M
    Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?
    Sabel MS; Sondak VK
    Drugs; 2003; 63(11):1053-8. PubMed ID: 12749732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.